Phaseline

Targets › PTPRC

PTPRC (Receptor-type tyrosine-protein phosphatase C): drug programs, companies and trials

8 programs from 8 companies in 9 trials: 6 Phase 1, 3 Phase 2; Oncology, Hematology, Other; next expected readout Dec 2026.

Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. (UniProt, P08575)

Open in Phaseline: the race on PTPRC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assistance Publique - Hôpitaux de ParisRabbit ATG
Anti-thymocyte globulin; depletes T cells
PTPRCPhase 2Refractory Idiopathic Aplastic AnemiaJan 2027
Northside Hospital, Inc.Rabbit ATG
Polyclonal anti-T cell antibody targeting T lymphocytes
PTPRCPhase 2Severe Aplastic AnemiaAug 2027
Hong Kong Children's HospitalCD45RA depleted DLI
Donor lymphocyte infusion with CD45RA-positive cells depleted
PTPRCPhase 2Hematopoietic Cell TransplantationOct 2029
University Hospital, GenevaCD45RA-depleted donor lymphocyte infusion (DLI)
CD45RA-depleted T cell therapy - selective depletion of naive T cells expressing CD45RA an
PTPRCPhase 1Hematologic MalignancyDec 2026
Ruijin HospitalCD45RA depleted donor lymphocyte infusion (DLI)
CD45RA-depleted donor lymphocyte infusion; selective depletion of naive T cells via CD45RA
PTPRCPhase 1Hematologic MalignancyJun 2027
Fred Hutchinson Cancer CenterAstatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Anti-CD45 monoclonal antibody labeled with radioactive astatine-211
PTPRCPhase 1Non-Malignant Neoplasm; Acute Lymphoblastic Leukemia in RemissionJan 2028
University Hospital TuebingenCD45RA depleted donor lymphocyte infusion (DLI)
CD45RA depleted donor lymphocyte infusion after TCRα/β depleted haploidentical hematopoiet
PTPRCPhase 1Hematologic MalignancyJan 2028
Paul SzabolcsCD45RA depleted leukocytes
Negative selection depleting CD45RA+ naive T cells from donor bone marrow via CliniMACS im
PTPRCPhase 1Sickle Cell AnemiaAug 2028

Conditions

Hematologic Malignancy (3) Severe Aplastic Anemia (1) Sickle Cell Anemia (1) Non-Malignant Neoplasm (1) Acute Lymphoblastic Leukemia in Remission (1) Hematopoietic Cell Transplantation (1) Refractory Idiopathic Aplastic Anemia (1)

Modalities

protein or peptide (3), mixed (2), small molecule (1)

Companies

Northside Hospital, Inc. (1) Paul Szabolcs (1) Fred Hutchinson Cancer Center (1) Ruijin Hospital (1) Hong Kong Children's Hospital (1) University Hospital Tuebingen (1) Assistance Publique - Hôpitaux de Paris (1) University Hospital, Geneva (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.